FDA Awards Orphan Drug Designation to KT-253 in AML
The FDA has granted an orphan drug designation to the novel, highly potent, and selective MDM2 degrader KT-253 for the treatment of patients with acute myeloid leukemia.
Source: onclive.com
Fast, Ad-Free News Updates
Stay updated with breaking news from Kt 253. Real-time updates on events, politics, business and more.